Madrigal Pharmaceuticals, Inc. Share Price
Stocks
MDGL
US5588681057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 535.27 USD | +3.87% |
|
+5.46% | -8.08% |
| 11/08 | Madrigal Pharmaceuticals, Inc. Presents at Canaccord Genuity's 46th Annual Growth Conference, Aug-11-2026 12:00 PM | |
| 30/07 | Madrigal Pharmaceuticals Q2 Loss Widens, Revenue Increases | MT |
| Market Cap | 1.24TCr 1.07TCr 1TCr 915.45Cr 1.72TCr 1,18000Cr 1.75TCr 12TCr 4.61TCr 59TCr 4.64TCr 4.54TCr 1,97000Cr | P/E 2026 * |
-84.8x | P/E 2027 * | 85x |
|---|---|---|---|---|---|
| Enterprise Value | 1.18TCr 1.03TCr 960.75Cr 876.62Cr 1.65TCr 1,13000Cr 1.68TCr 11TCr 4.41TCr 57TCr 4.45TCr 4.35TCr 1,88600Cr | EV / Sales 2026 * |
7.76x | EV / Sales 2027 * | 5.33x |
| Free-Float |
94.13% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Madrigal Pharmaceuticals, Inc.
| 1 day | +3.87% | ||
| 1 week | +5.46% | ||
| Current month | +14.54% | ||
| 1 month | -0.27% | ||
| 3 months | +7.69% | ||
| 6 months | +11.28% | ||
| Current year | -8.08% |
| 1 week | 501.21 |  | 535.57 |
| 1 month | 447.01 | | 566.18 |
| Current year | 416.21 | | 598.79 |
| 1 year | 351.32 | | 615 |
| 3 years | 119.76 | | 615 |
| 5 years | 52.33 | | 615 |
| 10 years | 7.46 | | 615 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Sibold
CEO | Chief Executive Officer | 59 | 08/09/2023 |
Mardi Dier
DFI | Director of Finance/CFO | 62 | 11/03/2024 |
David Soergel
CTO | Chief Tech/Sci/R&D Officer | 58 | 21/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Rebecca Taub
BRD | Director/Board Member | 74 | 01/07/2016 |
Richard Levy
BRD | Director/Board Member | 68 | 11/08/2016 |
James Daly
BRD | Director/Board Member | 64 | 27/06/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 20/07/26 | Sell | Chief Executive Officer | -2,500 | 0.0108% | ||
| 17/06/26 | Free | Director | 1,220 | 0.0053% | ||
| 23/02/26 | Fiscal year | Director | 5,000 | 0.0220% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.87% | +5.46% | +53.15% | +212.24% | 1.24TCr | |
| -0.70% | +13.34% | +75.61% | +103.83% | 7.05TCr | |
| -0.11% | -0.05% | +35.45% | +63.68% | 5.41TCr | |
| -1.62% | +34.25% | +17.43% | +491.04% | 2.9TCr | |
| -0.61% | +12.51% | +54.60% | +7.40% | 2.4TCr | |
| 0.00% | +1.59% | -15.06% | -13.21% | 2.33TCr | |
| +9.77% | +20.16% | +260.17% | +472.38% | 1.87TCr | |
| -0.60% | +4.60% | +42.99% | -21.93% | 1.84TCr | |
| 0.00% | +7.46% | +30.95% | +623.97% | 1.61TCr | |
| -3.08% | -8.34% | +37.21% | +138.52% | 1.27TCr | |
| Average | +0.69% | +8.33% | +59.25% | +207.79% | 2.79TCr | |
| Weighted average by Cap. | +0.23% | +9.05% | +57.29% | +170.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 152.63Cr 132.27Cr 123.83Cr 112.98Cr 212.61Cr 15TCr 216.18Cr 1.45TCr 568.87Cr 7.29TCr 573.08Cr 560.59Cr 24TCr | 214.49Cr 185.88Cr 174.01Cr 158.77Cr 298.78Cr 20TCr 303.8Cr 2.04TCr 799.42Cr 10TCr 805.34Cr 787.79Cr 34TCr |
| Net income | -18Cr -16Cr -15Cr -14Cr -26Cr -1.75TCr -26Cr -174.91Cr -69Cr -877.77Cr -69Cr -68Cr -2.93TCr | 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 28Cr 190.25Cr 75Cr 954.77Cr 75Cr 73Cr 3.19TCr |
| Net Debt | -52Cr -45Cr -43Cr -39Cr -73Cr -5TCr -74Cr -498.96Cr -195.49Cr -2.5TCr -196.94Cr -192.65Cr -8.35TCr | -94Cr -82Cr -77Cr -70Cr -131.39Cr -9TCr -133.6Cr -897.25Cr -351.55Cr -4.5TCr -354.15Cr -346.44Cr -15TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/26/11 | $535.27 | +3.87% | 4,15,197 |
| 10/26/10 | $515.34 | +1.04% | 2,83,738 |
| 07/26/07 | $510.04 | -0.06% | 3,47,529 |
| 06/26/06 | $510.36 | -0.73% | 2,96,763 |
| 05/26/05 | $514.12 | +1.29% | 3,49,534 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MDGL Stock
Select your edition
All financial news and data tailored to specific country editions
